Trials / Completed
CompletedNCT02167594
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flortaucipir F18 | IV injection, 370 megabecquerel (MBq) (10 mCi) |
| PROCEDURE | Brain PET scan | positron emission tomography (PET) scan of the brain 75-105 minutes post-injection |
Timeline
- Start date
- 2014-08-12
- Primary completion
- 2016-07-11
- Completion
- 2016-07-11
- First posted
- 2014-06-19
- Last updated
- 2020-08-28
- Results posted
- 2020-08-28
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02167594. Inclusion in this directory is not an endorsement.